About
R&D
Approach
Therapeutic areas
Scientific publications
R&D centers
Scientific and medical board
Scientific partnerships
Pipeline
Overview
TOTUM•63
Lipidrive® (TOTUM•070)
TOTUM•854
TOTUM•448
Manufacturing
Investors
Presentation
Shareholder space
Financial Information
Breakdown of Share Capital
Financial Calendar
Regulatory information
Annual General Meeting
Newsroom
News
Releases
Media resources
FR
EN
E-Shop
European Association for the Study of Diabetes (EASD) Congress
Accueil
»
European Association for the Study of Diabetes (EASD) Congress
Valbiotis presents its data on the multi-target mode of action of TOTUM•63, active principle of VALEDIA®, on October 4, 2018 (poster).